ClinicalTrials.gg
CompletedNCT01256762Updated Jan 26, 2016

Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer

A Phase 2 interventional study of Imetelstat sodium and Bevacizumab in Locally Recurrent or Metastatic Breast Cancer, sponsored by Geron Corporation. Completed at 55 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-01-26.

Sponsored by Geron Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
166
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 131 studies testing bevacizumab in Breast Neoplasms — 9 open to participants now, 10 under way, none of them phase 3. Bevacizumab · Breast Neoplasms.

Enrollment
25th of 130
166 · median 58
Started
2010
with 12 others
Phase 2
89 of 131
6 open now
Registered
104th of 131
by date

Among the 131 studies testing bevacizumab in Breast Neoplasms, this one is the 25th largest by enrollment of the 130 interventional ones that give a count, is one of 13 that started in 2010, is one of 89 in phase 2, and was the 104th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

9 of the 131 studies testing bevacizumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies testing bevacizumab in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of treatment with imetelstat + paclitaxel (with or without bevacizumab) versus paclitaxel (with or without bevacizumab) alone for patients with locally recurrent or metastatic breast cancer who have not received chemotherapy or have received one non-taxane based chemotherapy for metastatic breast cancer.

Read the detailed description

Patients will be randomized in a 1:1 ratio to imetelstat + paclitaxel (with or without bevacizumab) versus paclitaxel (with or without bevacizumab) alone.

03

Conditions studied

  • Locally Recurrent or Metastatic Breast Cancer

Browse trials for

Keywords

  • imetelstat
  • imetelstat sodium
  • GRN163L
  • telomerase inhibitor
  • telomerase inhibition
  • metastatic breast cancer
  • locally recurrent breast cancer
  • Bevacizumab
  • Paclitaxel
  • Avastin
  • Taxol
  • HER-2-negative
  • First-Line Chemotherapy
  • Second-Line Chemotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed adenocarcinoma of the breast that is either locally recurrent or . Locally recurrent disease must not be amenable to surgical resection or radiation with curative intent
  • Either have not received chemotherapy or may have had one prior non-taxane chemotherapy regimen for metastatic disease (there are no restrictions on prior hormonal therapy)
  • Prior use of bevacizumab is allowed provided that it was not administered in combination with a taxane
  • performance status 0-1
  • Adequate bone marrow reserve as indicated by:

    • > 1500/uL (without use of growth factors within 7 days)
    • count > 100,000 (without transfusion in prior 7 days)
    • > 9.0 g/dL

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or breast feeding
  • Locally recurrent disease amenable to resection with curative intent
  • -positive breast cancer
  • Active central nervous system (CNS) disease including those patients receiving radiotherapy and/or treatment (within the last 3 months)
  • Prior or neoadjuvant taxane chemotherapy within 12 months prior of first relapse
  • therapy within 4 weeks of first study drug administration
  • Prior radiation, cytotoxic, or hormonal therapy within 2 weeks of first study drug administration
  • Therapeutic anti-coagulation or regular use of anti- therapy within 2 weeks prior to first study drug administration (low dose anti-coagulant therapy to maintain patency of a vascular access device is allowed)
  • Grade ≥ 2 neuropathy
  • Uncontrolled atrial or ventricular arrhythmias (unless pacemaker in place)
  • Severe conduction disturbance including clinically significant QTC prolongation > 450 ms (unless pacemaker in place)
  • Active or chronically recurrent bleeding (e.g., active peptic ulcer disease)
  • Clinically relevant active infection
  • Known positive serology for (HIV)
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
166 participants (actual)

Study arms

  • Experimental
    Imetelstat + Paclitaxel (with or without bevacizumab)

    Drug: Imetelstat sodium · Drug: Bevacizumab · Drug: Paclitaxel

  • Experimental
    Paclitaxel (with or without bevacizumab) alone

    Drug: Bevacizumab · Drug: Paclitaxel

Interventions

  • Imetelstat is administered at a dose of 300 mg/m2 on day one of a 21 day cycle.

    Also known as: GRN163L

  • Bevacizumab is administered at 15 mg/kg on day one of a 21 day cycle

    Also known as: Avastin

  • Paclitaxel is administered at 90 mg/m2 on days one and eight of a 21 day cycle

    Also known as: Taxol

06

What researchers measure

Primary outcomes

  1. Progression-free survival

    Defined as the time from randomization to documented disease progression, as determined by the investigator's assessment according to RECIST, or death from any cause, whichever occurs first.

    Time frame: Occurring post randomization through end of study period (9 mos. after the last participant is randomized)

Secondary outcomes

  1. Objective response

    Objective response as determined by the investigator according to RECIST for patients with measurable disease at baseline.

    Time frame: Occurring post randomization through end of study period (9 mos. after the last participant is randomized)

  2. Clinical benefit rate

    Clinical response rate includes patients with objective response and stable disease lasting at least 6 months.

    Time frame: Occurring post randomization through end of study period (9 mos. after the last participant is randomized)

07

Study locations

55 sites
  • Clearview Cancer Center
    Huntsville, Alabama 35805, United States
  • Alta Bates Summit Medical Center
    Berkeley, California 94704, United States
  • Southbay Oncology Hematology Partners
    Campbell, California 95008, United States
  • Cancer Care Associates
    Fresno, California 93720, United States
  • Memorial Miller Hospital
    Long Beach, California 90806, United States
  • St. Joseph Hospital
    Orange, California 92868, United States
  • Desert Regional Comprehensive Cancer Center
    Palm Springs, California 92262, United States
  • UC San Diego
    San Diego, California 92093, United States
  • Redwood Regional Medical Group
    Santa Rosa, California 95403, United States
  • Univ. Colorado at Denver
    Aurora, Colorado 80045, United States
  • Connecticut Oncology & Hematology
    Torrington, Connecticut 06790, United States
  • Medical Oncology Hematology
    Waterbury, Connecticut 06708, United States
  • Florida Oncology Associates
    Jacksonville, Florida 32256, United States
  • Hematology Oncology Associates
    Port St. Lucie, Florida 34952, United States
  • H. Lee Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Northeast Georgia Cancer Care
    Athens, Georgia 30607, United States
  • Peachtree Hematology Oncology
    Atlanta, Georgia 30318, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Northeast Georgia Medical Center
    Gainesville, Georgia 30501, United States
  • Central Georgia Cancer Care
    Macon, Georgia 31201, United States
  • Summit Cancer Care
    Savannah, Georgia 31405, United States
  • Kootenai Medical Center
    Post Falls, Idaho 83854, United States
  • Ingalls Memorial Hospital
    Chicago, Illinois 60426, United States
  • Rush University
    Chicago, Illinois 60612, United States
  • Mid Illinois Hematology & Oncology
    Normal, Illinois 61761, United States
  • Cancer Treatment Centers of America
    Zion, Illinois 60099, United States
  • Indiana University
    Indianapolis, Indiana 46202, United States
  • Community Hospitals of Indiana
    Indianapolis, Indiana 46268, United States
  • Horizon Oncology Center
    Lafayette, Indiana 47905, United States
  • Cancer Center of Kansas
    Wichita, Kansas 67214, United States
  • Montgomery Cancer Care
    Mount Sterling, Kentucky 40353, United States
  • Michigan State University
    East Lansing, Michigan 48823, United States
  • New Mexico Cancer Center
    Albuquerque, New Mexico 87109, United States
  • Prohealth Associates
    Lake Success, New York 11402, United States
  • Stony Brook University
    Stony Brook, New York 11794, United States
  • Carolinas Hematology/Oncology
    Charlotte, North Carolina 28203, United States
  • Moses Cone Medical System
    Greensboro, North Carolina 27403, United States
  • Case Western Reserve Univ.
    Cleveland, Ohio 44106, United States
  • Mercy Physicians of Oklahoma
    Oklahoma City, Oklahoma 73120, United States
  • Cancer Care Associates
    Tulsa, Oklahoma 74136, United States
  • Kaiser Northwest
    Portland, Oregon 97232, United States
  • Pinnacle Health
    Harrisburg, Pennsylvania 17110, United States
  • Penn. State Univ.
    Hershey, Pennsylvania 17033, United States
  • The Jones Clinic
    Germantown, Tennessee 38138, United States
  • The West Clinic
    Memphis, Tennessee 38120, United States
  • Scott & White Healthcare
    Temple, Texas 76508, United States
  • Northern Utah Associates
    Ogden, Utah 84403, United States
  • Peninsula Cancer Institute
    Newport News, Virginia 23601, United States
  • Medical Oncology Associates
    Spokane, Washington 99208, United States
  • Northwest Medical Specialties
    Tacoma, Washington 98405, United States
  • Grand River Regional Cancer Centre
    Kitchener, Ontario N2G 1G3, Canada
  • Stronach Regional Cancer Centre at Southlake
    Newmarket, Ontario L3Y 2P9, Canada
  • The Ottawa Hospital Cancer Centre
    Ottawa, Ontario K1H 8L6, Canada
  • Sunnybrook Health Services Centre
    Toronto, Ontario M4N 3M5, Canada
  • McGill University
    Montreal, Quebec H2W 1S6, Canada
08

References and documents

Publications

  • Hochreiter AE, Xiao H, Goldblatt EM, Gryaznov SM, Miller KD, Badve S, Sledge GW, Herbert BS. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer. Clin Cancer Res. 2006 May 15;12(10):3184-92. doi: 10.1158/1078-0432.CCR-05-2760. PubMed 16707619 ↗
  • Goldblatt EM, Gentry ER, Fox MJ, Gryaznov SM, Shen C, Herbert BS. The telomerase template antagonist GRN163L alters MDA-MB-231 breast cancer cell morphology, inhibits growth, and augments the effects of paclitaxel. Mol Cancer Ther. 2009 Jul;8(7):2027-35. doi: 10.1158/1535-7163.MCT-08-1188. Epub 2009 Jun 9. PubMed 19509275 ↗
  • Herbert BS, Wright WE, Shay JW. Telomerase and breast cancer. Breast Cancer Res. 2001;3(3):146-9. doi: 10.1186/bcr288. Epub 2001 Feb 22. PubMed 11305948 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Oct 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2010
First posted
Dec 9, 2010
Start
Nov 2010
Primary completionActual
Oct 2012
CompletionActual
Dec 2012
Results delay requested
Mar 13, 2015
Last update
Jan 26, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01256762
Lead sponsor
Geron Corporation
Responsible party
Sponsor
First posted
Dec 9, 2010
Start date
Nov 2010
Primary completion
Oct 2012
Completion
Dec 2012
Last update
Jan 26, 2016

Study contacts

Ted Shih, PharmD
study director · Geron Corporation
Kathy Miller, MD
principal investigator · Indiana University School of Medicine

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bevacizumab · Paclitaxel

Start the discussion